Alzumab-L — Itolizumab
Itolizumab targets CD6, a less commonly addressed pathway in autoimmune disease compared to the TNF and IL-inhibitor mechanisms most other biologics in our catalogue use — originally developed in Cuba and now manufactured under license in India, it remains genuinely harder to source globally than Adalimumab or Infliximab, which gives distributors seeking a differentiated specialty-immunotherapy portfolio a real point of distinction when positioning it to hospitals and clinics.
- Approved indications: Moderate-to-severe chronic plaque psoriasis, rheumatoid arthritis
- Mechanism: Binds CD6 on T-cells, modulating T-cell activation and reducing the inflammatory response driving psoriasis and rheumatoid arthritis
- Global availability: Notably less widely available than mainstream TNF-inhibitor biologics — a sourcing advantage worth highlighting when quoting distributors seeking differentiated inventory
- Tolerability profile: Generally well-tolerated, with mild infusion-related reactions being the most commonly reported adverse event in trials
Key Product Facts
100 mg
Strength
1 Vial
Pack Size
Itolizumab
Active Ingredient
Immunology
Category
Enquire Now for Pricing
Price
Itolizumab targets CD6, a less commonly addressed pathway in autoimmune disease compared to the TNF and IL-inhibitor mechanisms most other biologics in our catalogue use — originally developed in Cuba and now manufactured under license in India, it remains genuinely harder to source globally than Adalimumab or Infliximab, which gives distributors seeking a differentiated specialty-immunotherapy portfolio a real point of distinction when positioning it to hospitals and clinics.
- Approved indications: Moderate-to-severe chronic plaque psoriasis, rheumatoid arthritis
- Mechanism: Binds CD6 on T-cells, modulating T-cell activation and reducing the inflammatory response driving psoriasis and rheumatoid arthritis
- Global availability: Notably less widely available than mainstream TNF-inhibitor biologics — a sourcing advantage worth highlighting when quoting distributors seeking differentiated inventory
- Tolerability profile: Generally well-tolerated, with mild infusion-related reactions being the most commonly reported adverse event in trials
- Infection risk: Elevated — active infections should be resolved before starting treatment
- Vaccination: Live vaccines should be avoided during treatment
- Immunosuppression history: Requires caution and closer monitoring
- Infusion monitoring: Recommended given documented infusion-related reaction risk, though generally mild in severity
| Document |
Included |
| Certificate of Analysis (COA) |
Standard |
| Certificate of Origin (COO) |
Standard |
| MSDS |
Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold-chain export (2–8°C)
- Coverage: Global export markets
- Tracking: Full shipment tracking included
What is Itolizumab used for?
Treats moderate-to-severe chronic plaque psoriasis and rheumatoid arthritis.
Get Itolizumab price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
How is it different from other autoimmune biologics?
It targets CD6, a less commonly addressed pathway, and is notably harder to source globally than TNF-inhibitors.
Who supplies Itolizumab from India?
WHO-GMP certified manufacturer with full export documentation.
Is it well-tolerated?
Yes, generally well-tolerated with mild infusion reactions being the most common side effect reported.
